US › Healthcare

Compass Therapeutics Inc. (CMPX)

US · Healthcare · Biotechnology

$1.85+1.09%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-25.2M

EPS

$-0.13

EPS estimate

$-0.10

EPS came in at -0.13 against a street estimate of -0.10 — a miss of 30.0%.

Key statistics

Market cap

$329.6M

Forward P/E

0.0

P/B

2.01

Book value

$0.92

EPS (TTM)

$-0.38

52-week high

$6.88

52-week low

$1.61

50-day MA

$2.20

200-day MA

$3.89

Beta

0.84

Analyst view

Analysts rate Compass Therapeutics Inc. a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $8.92.

Shareholding

Insiders

12.46%

Institutions

88.57%

Largest institutional holders

Fund	Stake
TANG CAPITAL MANAGEMENT LLC	9.32%
Orbimed Advisors LLC	8.45%
Suvretta Capital Management, LLC	7.94%
BlackRock Inc	5.28%
Enavate Sciences GP, LLC	4.32%
Bvf Inc	4.31%
Vivo Capital, LLC	4.31%
State Street Corp	3.72%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Compass Therapeutics Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.